Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of 200 IU OnabotulinumtoxinA (Botulinum Toxin Type A) in Patients With Idiopathic

NCT06408051 is registered in ClinicalTrials.gov with Hisar Intercontinental Hospital as lead sponsor.

NCT NCT06408051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06408051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of 200 IU OnabotulinumtoxinA (Botulinum Toxin Type A) in Patients With Idiopathic
Lead sponsor
Hisar Intercontinental Hospital
Phase
Observational
Overall status
Completed
Start date
January 1, 2020
Completion date
July 31, 2023
Enrollment
60 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic overactive bladder resistant to anticholinergic treatment